Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients

Anthropometric reference data for elderly Swedes and its disease-related pattern

(2015) N N Gavriilidou et al.   EUROPEAN JOURNAL OF CLINICAL NUTRITION

Quality of Life Among Women Treated for Breast Cancer: A Survey of Three Procedures in Mexico

(2014) Ana Olivia Cortés-Flores et al.   AESTHETIC PLASTIC SURGERY

Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2014) Ann H. Partridge et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival Benefit From Response-Guided Approach: A Direct Effect of More Effective Cytotoxic Regimens or an Indirect Effect of Chemotherapy-Induced Amenorrhea?

(2014) Ke-Da Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

(2014) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

(2014) Bruno Coudert et al.   LANCET ONCOLOGY

Improving early cycle economic evaluation of diagnostic technologies

(2014) Lotte MG Steuten et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Selecting the neoadjuvant treatment by molecular subtype: How to maximize the benefit?

(2013) Gunter von Minckwitz et al.   BREAST

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer

(2013) Bas B. Koolen et al.   BREAST

Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer

(2013) Jennifer F. De Los Santos et al.   CANCER

Insight or Confusion: Survival After Response-Guided Neoadjuvant Chemotherapy in Breast Cancer

(2013) Melinda L. Telli   JOURNAL OF CLINICAL ONCOLOGY

Response-Guided Neoadjuvant Chemotherapy for Breast Cancer

(2013) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Imaging of triple-negative breast cancer

(2012) B. E. Dogan et al.   ANNALS OF ONCOLOGY

Neoadjuvant treatments for triple-negative breast cancer (TNBC)

(2012) G. von Minckwitz et al.   ANNALS OF ONCOLOGY

Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?

(2012) Lian-Ming Wu et al.   BREAST CANCER RESEARCH AND TREATMENT

Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia

(2012) Emily Ford et al.   BMJ Open

Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype

(2011) Claudette E. Loo et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of direct medical costs of hospitalization for febrile neutropenia

(2009) Nina Lathia et al.   CANCER

Health state utilities for non small cell lung cancer

(2008) Beenish Nafees et al.   Health and Quality of Life Outcomes

Quality of life over 5 years in women with breast cancer after breast-conserving therapy versus mastectomy: a population-based study

(2008) Volker Arndt et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions

(2008) Julie R. Gralow et al.   JOURNAL OF CLINICAL ONCOLOGY